Research

Arthur J. Hudson Translational Grant

The Arthur J. Hudson Translational Team Grant was first announced on May 3, 2014 at the ALS Canada Research Forum and the inaugural competition deadline was July 1, 2014. This new grant program is designed to fund teams of Canadian researchers to accelerate the movement of ideas out of the laboratory and into the clinic with the hope of assisting development of new therapeutics for ALS. It is the cornerstone of our ALS Canada Research Program designed to emphasize bench-to-bedside translation. For the first time ever, ALS Canada, in partnership with Brain Canada, have utilized an International Peer Review Panel consisting of seven European and American ALS experts, spanning the basic to clinical spectrum, who convened in Toronto in November to determine the top project amongst strong competition.  Read More...

 

Statement from ALS Canada regarding dexpramipexole research results

Today Biogen Idec reported results from a Phase 3 trial investigating dexpramipexole (dex) in people with amyotrophic lateral sclerosis (ALS). The company said that the trial failed to show slowing of functional decline or improved survival and failed to demonstrate efficacy. Based on these results, the company is discontinuing development of dexpramipexole in ALS. Earlier research trials showed benefits with dexpramipexole; however late-stage clinical research failed to show improvement.
Read More »

 

Canadians Team Shows C9orf72 Mutation is Specific to ALS and FTD

Last year, two international collaborations revealed that pieces of DNA called introns, previously thought to be of little importance, were directly involved in both ALS and frontotemporal dementia (FTD).Elongated pieces of introns in a gene called C9orf72 were found to be the cause of the highest percentage of hereditary ALS and FTD.
Read More »

Canadian Researchers Discover New ALS Gene Mutation

In what he describes as, "a purely Canadian discovery", Dr. Michael Strong's laboratory at Western University have discovered a new gene that causes ALS. Last year, a project led by postdoctoral fellow Dr. Cristian Droppelmann described a protein called rho guanine nucleotide exchange factor (RGNEF) which was identified in clumps (called aggregates or inclusions) that appear inside of sick motor neurons and have long been associated with the disease pathology. 
Read More ...

 

Glucose Intake Has Surprising Effect on Neuroprotection

Aging is something we all have in common. Over the past decade, tremendous breakthroughs have been made towards scientifically understanding mechanisms that control aging.
For nearly a century scientists have known that regulation of metabolism and energy production through dietary restriction could extend lifespan in various species, including a 20-year study in rhesus monkeys reported in 2009. Since neurodegenerative diseases are often classified as diseases of aging, it is commonly believed that slowing aging would have positive effects on neuronal health.
Read More »

 

Valosin-Containing Protein/ALS Connection Strengthened

Mutations in the gene for an enzyme called valosin-containing protein (VCP) are known to directly cause a disease called Inclusion Body Myopathy associated with Paget’s disease of bone and frontotemporal dementia.
Read More »

For more information on ALS Research visit www.als.ca